$18.610
-0.618 (-3.32%)Zum Schluss
OMER-News
OMER-Events
Major Averages Rise as Oil Prices Fall
The major averages closed broadly higher as oil prices fell and investors digested softer-than-feared inflation data and another slate of corporate earnings reports.The Fed outlook has become somewhat more favorable for equities following the inflation data and the weak July employment report. Meanwhile, oil prices were down as concerns over global demand and rising U.S. crude inventories offset continued geopolitical risks surrounding Iran and the Strait of Hormuz.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Ciscoreportedand provided an upbeat outlook for Q1 and FY27Cerebras Systemsreportedbut raised its FY26 revenue guidancePershing Squarereported Netflixand VisaamongTapestryreported, provided its outlook for Q1 and FY27, and approved a 16% dividend increaseSilver Lake is in talks to acquire Workday,2. WALL STREET CALLS:Five Belowto Buy at JefferiesStubHubto Underperform at BofAVail Resortswith a Sell at Goldman SachsJPMorganAkamaito Neutral on revenue growth rampTronoxto Underweight at JPMorgan3. AROUND THE WEB:AMDis planning its largest-ever investment-grade bond offering of up to $5B across four maturities, Bloomberg reportsAlphabetchief scientist Demis Hassabis discussed forming an independent AI safety entity before stepping down as Google DeepMind CEO, WSJ saysFordplans to shift production of some China-built Lincoln models to the U.S. starting in 2030, driven primarily by tariffs, including a 52.5% duty on the China-made Nautilus, and the goal of strengthening domestic manufacturing, Reuters reportsBending Spoons'acquisition strategy is driving strong financial results and aggressive software monetization, but steep price increases for legacy customers risk accelerating churn and undermining the long-term value of its acquired businesses, Bloomberg saysAppleis in talks with publishers over new deals to use their content to deliver current news and information as part of the iPhone maker's efforts to improve its AI-powered Siri voice assistant, WSJ reports4. MOVERS:Accelerantgained after announcingin an all-cash deal worth more than $4B and reporting Q2 resultsSanDiskrose afterfor the years 2028 through 2030 at its investor day meetingOmerosand CorMedixwere higher afterCellebritefell afterand cutting its guidance for FY26Securitizeand Resideowere lower after5. EARNINGS/GUIDANCE:Yetiand raised its outlook for FY26Paysafe, with CEO Bruce Lowthers commenting on "strong traction across our priority markets and products"Cellebrite, provided guidance for Q3, and cut its outlook for FY26Ondas, provided guidance for Q3, and cut its outlook for FY26Yeswayand increased its outlook for FY26INDEXES:The Dow rose 69.72, or 0.13%, to 53,839.99, the Nasdaq gained 214.54, or 0.81%, to 26,803.03, and the S&P 500 advanced 50.49, or 0.65%, to 7,798.99.
Major Averages Rise as Oil Prices Fall
The major averages were broadly higher again near noon as oil prices fell and investors digested softer-than-feared inflation data and another slate of corporate earnings reports.The Fed outlook has become somewhat more favorable for equities following the inflation data and the weak July employment report. Markets are now pricing roughly a 66% probability that the Fed holds rates steady at its next meeting, according to Reuters.Meanwhile, oil prices are down a bit as concerns over global demand and rising U.S. crude inventories offset continued geopolitical risks surrounding Iran and the Strait of Hormuz.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Ciscoreportedand provided an upbeat outlook for Q1 and FY27Cerebras Systemsreported mixed Q2 results butPershing Squarereported Netflixand VisaTapestryreported, provided its outlook for Q1 and FY27, and approved a 16% dividend increaseJD.comreported better-than-expected2. WALL STREET CALLS:Five Belowto Buy at JefferiesStubHubto Underperform at BofAVail Resortswith a Sell at Goldman SachsJPMorganAkamaito Neutral on revenue growth rampTronoxto Underweight at JPMorgan3. AROUND THE WEB:Former Alibabastar researcher Junyang Lin is launching Shanghai-based Pragmatik Labs to build digital and physical AI agents, The Information reportsAlphabetchief scientist Demis Hassabis discussed forming an independent AI safety entity before stepping down as Google DeepMind CEO, WSJ saysFordplans to shift production of some China-built Lincoln models to the U.S. starting in 2030, driven primarily by tariffs, including a 52.5% duty on the China-made Nautilus, and the goal of strengthening domestic manufacturing, Reuters reportsBending Spoons'acquisition strategy is driving strong financial results and aggressive software monetization, but steep price increases for legacy customers risk accelerating churn and undermining the long-term value of its acquired businesses, Bloomberg saysAppleis in talks with publishers over new deals to use their content to deliver current news and information as part of the iPhone maker's efforts to improve its AI-powered Siri voice assistant, WSJ reports4. MOVERS:Accelerantgains after announcing it will bein an all-cash deal worth more than $4B and reporting Q2 resultsBirkenstockrises in New York afterand raising its guidance for FY26Omerosand CorMedixhigher afterCellebritefalls afterand cutting its guidance for FY26Securitizeand Resideolower after5. EARNINGS/GUIDANCE:Yetiand raised its outlook for FY26Paysafe, with CEO Bruce Lowthers commenting on "strong traction across our priority markets and products"Cellebrite, provided guidance for Q3, and cut its outlook for FY26Ondas (ONDS), provided guidance for Q3, and cut its outlook for FY26Yeswayand increased its outlook for FY26INDEXES:Near midday, the Dow was down 65.19, or 0.12%, to 53,705.08, the Nasdaq was up 150.61, or 0.57%, to 26,739.10, and the S&P 500 was up 33.77, or 0.44%, to 7,782.27.
Nasdaq 100 Contract Down 0.2%, Cisco Down 4.1%
Index futures are mixed in the opening hours of the evening session, with S&P e-minis flat, Dow Industrials up marginally, and Nasdaq 100 contract down by 0.2%. Softer than expected inflation data compressed yields and helped to propel the AI trade on Wednesday with many of this year's winners in Semiconductors, Semi Equipment, Memory, and Hardware leading the charge. The momentum of that exuberance could be fleeting however after post-earnings selloffs in some of the larger AI-themed stocks - Cisco slid 4% while Cerebras Systems retreated 16% afterhours.In commodities, WTI Crude Oil has continued to consolidate this month's advance with a 1% decline below $82.70. Precious metals are rangebound, though traders are positioning for renewed interest as expectations of Fed tightening recedes following the latest tamer inflation and softer labor economic reports.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Harmonicup 19.2%Omerosup 18.7%EnerSysup 11.4%Grocery Outletup 10.6%Jack in the Boxup 5.2%DOWN AFTER EARNINGS -Cerebras Systemsdown 16.1%StubHub Holdingsdown 13.7%Resideo Technologiesdown 7.6%Pan American Silverdown 5.5%Coherentdown 4.2%Cisco Systemsdown 4.1%
Omeros Q2 Revenue $32.2M, Exceeds Expectations
Reports Q2 revenue $32.2M, consensus $12.67M. "We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA's commercial launch," said Gregory A. Demopulos, M.D., Omeros' Chairman and Chief Executive Officer. "Equally gratifying are the consistent reports from transplant physicians nationwide describing responses to YARTEMLEA in their adult and pediatric patients, including those who had not responded to prior off-label C5 inhibitor administration. YARTEMLEA is saving lives and, with FDA approval, is now broadly accessible in the U.S. Substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure. We repurchased an additional 489,000 shares of common stock in the open market and reduced the outstanding principal amount of our 2029 convertible notes by 43%, eliminating nearly $9 million in future cash interest payments and approximately 5 million additional shares of potential dilution. At the same time, our work with Novo Nordisk on the MASP-3 inhibitor zaltenibart remained on track toward Phase 3 trial initiation, while our complement, addiction, oncology, and infectious disease programs continued advancing. Collectively, these programs position Omeros for a broad range of value-driving milestones over the next 18 months."
Omeros Receives NTAP Status for Yartemlea
Omeros Corporation announced that the Centers for Medicare & Medicaid Services, CMS, has granted New Technology Add-On Payment, NTAP, status for Yartemlea under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System, IPPS, Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy, TA-TMA, will receive additional Medicare reimbursement. Yartemlea is the first and only FDA-approved treatment for TA-TMA, a rare, life-threatening complication of hematopoietic stem cell transplantation, HCT. Approximately 30% of patients undergoing allogeneic HCT in the United States are Medicare beneficiaries, representing a growing segment of the transplant population at risk for TA-TMA.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.